Suppr超能文献

前列腺侵袭性导管腺癌的基因组分析。

Genomic analysis of aggressive ductal adenocarcinoma of the prostate.

机构信息

Department of Urology, Keio University School of Medicine, Tokyo, Japan.

Department of Urology, Saiseikai Yokohamashi Tobu Hospital, Kanagawa, Japan.

出版信息

Cancer Med. 2023 Apr;12(7):8445-8451. doi: 10.1002/cam4.5573. Epub 2022 Dec 26.

Abstract

BACKGROUND

Genomic profile analysis using next-generation sequencing can potentially elucidate the pathogenesis of rare cancers. Ductal adenocarcinoma, a rare subtype of prostate cancer, has an aggressive nature. This is the first study to analyze the genomic profile of ductal adenocarcinoma in an Asian population.

METHODS

We identified 12 patients newly diagnosed with ductal adenocarcinoma of the prostate at two hospitals, and nine patients (75.0%) had the pure type. Genomic assessment was performed using either the PleSSision testing platform or FoundationOne CDx.

RESULTS

At least one genomic alteration occurred in 11 patients (91.7%), and the most frequently mutated gene was tumor suppressor protein p53 (TP53), which was found in six cases (50.0%). Alterations characteristic of this cohort were found in four cases (33.3%) of retinoblastoma transcriptional corepressor 1 (RB1), which was only observed in the pure type. Compared to previous study results, the frequency of genetic alterations in the phosphoinositide 3-kinase (PI3K) pathway (n = 3; 25.0%) and Wnt-β-catenin pathway (n = 5; 41.7%) was comparable, but no alterations in the DNA damage repair (DDR) pathway were observed. None of the patients presented high tumor mutation burden or microsatellite instability.

CONCLUSIONS

We found that the Asian cohort with ductal adenocarcinoma had actionable alterations, and a high frequency of alterations in TP53 and RB1 reflected the aggressive nature of the tumor. Genetic analysis using next-generation sequencing is expected to help elucidate the pathogenesis of ductal adenocarcinoma.

摘要

背景

下一代测序的基因组分析有可能阐明罕见癌症的发病机制。导管腺癌是前列腺癌的一种罕见亚型,具有侵袭性。这是第一项在亚洲人群中分析导管腺癌基因组特征的研究。

方法

我们在两家医院鉴定了 12 例新诊断的前列腺导管腺癌患者,其中 9 例(75.0%)为纯型。使用 PleSSision 测试平台或 FoundationOne CDx 进行基因组评估。

结果

至少有 11 例患者(91.7%)发生了至少一次基因组改变,最常突变的基因是肿瘤抑制蛋白 p53(TP53),有 6 例(50.0%)发生了改变。在 4 例(33.3%)纯型患者中发现了视网膜母细胞瘤转录核心抑制因子 1(RB1)的特征性改变,这在该队列中仅观察到。与之前的研究结果相比,磷酸肌醇 3-激酶(PI3K)通路(n=3;25.0%)和 Wnt-β-连环蛋白通路(n=5;41.7%)的基因突变频率相当,但未观察到 DNA 损伤修复(DDR)通路的改变。没有患者出现高肿瘤突变负荷或微卫星不稳定。

结论

我们发现亚洲导管腺癌患者存在可治疗的改变,TP53 和 RB1 的高频改变反映了肿瘤的侵袭性。使用下一代测序进行遗传分析有望有助于阐明导管腺癌的发病机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb2a/10134333/cb86497369ce/CAM4-12-8445-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验